2027 Co-op Supply Chain & Clinical Drug Logistics
Regeneron Pharmaceuticals
Summary
Regeneron is currently seeking multiple 2027 Co-ops in Supply Chain & Clinical Drug Logistics to join our Global Development, Global Procurement, and other supply-chain-focused teams, which plan, package, and deliver investigational medicines to clinical trial sites worldwide while managing sourcing, procurement, and supply continuity across the organization.
Job description
When & where
Location: Warren, NJ and Tarrytown / Sleepy Hollow, NY. Timeframe: Our Co-op positions are full-time and onsite from January through May (Spring), January through August (Spring-Summer), and May/June-December (Summer-Fall).
What you'll do
- Build planning, forecasting, and inventory-management tools and dashboards to support clinical trial and supply chain operations
- Develop interactive web applications and resource maps that improve visibility and efficiency across the supply chain
- Support day-to-day clinical supply operations to help ensure the right medicine reaches the right trial site at the right time
- Research and evaluate suppliers, materials, and sourcing opportunities to support procurement and supply continuity
- Support supplier relationship management, category strategy development, and spend analytics activities
- Analyze data and apply digital tools, including artificial intelligence (AI) and automation platforms, to streamline supply chain processes and decision-making
- Document processes, maintain organized records, and contribute to continuous-improvement initiatives
- Collaborate with cross-functional teams and present findings and recommendations
Relevant majors
Supply Chain, Industrial Engineering, Operations Management, Data Science/Analytics, Computer Science
Let's find out if we're a fit
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Must be able to commit to 40 hours per week from January-August, May/June-December, or August-December
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred
- Cumulative GPA of 3.0 or higher preferred
Requirements
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Must be able to commit to 40 hours per week from January-August, May/June-December, or August-December
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred
- Cumulative GPA of 3.0 or higher preferred
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.